Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
Launched by GRUPPO ITALIANO PER LO STUDIO DEL MIELOMA MULTIPLO · Oct 4, 2005
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
Intermittent courses of Melphalan and Prednisone (MP) have been the first line therapy in multiple myeloma, for many years.
Advances in systemic and supportive therapy increased remission rates and overall survival, but multiple myeloma still remains an incurable haematological malignancy. Several preliminary studies demonstrate the efficacy of thalidomide in refractory and relapsed multiple myeloma with an overall response rate of 30 to 60%.
Due to its activity, Thalidomide will be evaluated in association with MP in a randomized study for newly diagnosed myeloma patients not eligible fo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • untreated myeloma patients
- • age \>65 years of age or younger but excluded from transplant procedure
- • Durie \& Salmon stage II or III myeloma and measurable disease.
- • Patients agreed to use contraception
- Exclusion Criteria:
- • other cancer
- • psychiatric disease and any grade 2 peripheral neuropathy
About Gruppo Italiano Per Lo Studio Del Mieloma Multiplo
The Gruppo Italiano per lo Studio del Mieloma Multiplo (GISMM) is a leading Italian research organization dedicated to advancing the understanding and treatment of multiple myeloma. Composed of a network of hematologists and oncology specialists, GISMM focuses on conducting high-quality clinical trials, fostering collaborative research, and promoting innovative therapies to improve patient outcomes. By prioritizing patient-centered approaches and integrating multidisciplinary expertise, GISMM aims to enhance the overall care and quality of life for individuals affected by this complex hematological malignancy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergamo, , Italy
Bologna, , Italy
Cuneo, , Italy
Foggia, , Italy
Monza, , Italy
Napoli, , Italy
Palermo, , Italy
Perugia, , Italy
Reggio Calabria, , Italy
Roma, , Italy
Roma, , Italy
Roma, , Italy
Torino, , Italy
Patients applied
Trial Officials
Mario Boccadoro, MD
Principal Investigator
Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S.Giovanni Battista, Torino, Italy
Antonio Palumbo, MD
Study Director
Divisione di Ematologia dell'Università degli Studi di Torino, Azienda Ospedaliera S.Giovanni Battista, Torino, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials